Walid A Hussain1, Deborah S Bondi2, Pooja Shah2, Sherwin E Morgan3, Sudhir Sriram4, Michael D Schreiber4. 1. Section of Neonatology, Department of Pediatrics (WAH), Loyola University Medical Center, Maywood, IL. 2. Department of Pharmacy (DSB, PS), University of Chicago Medicine Comer Children's Hospital, Chicago, IL. 3. Department of Respiratory Care Services (SEM), University of Chicago Medicine, Chicago, IL. 4. Section of Neonatology, Department of Pediatrics (SS, MDS), University of Chicago Medicine Comer Children's Hospital, Chicago, IL.
Abstract
OBJECTIVE: Inhaled nitric oxide (iNO) is an effective but expensive treatment of pulmonary hypertension in newborns, with limited data regarding weaning. Our institution implemented a multidisciplinary iNO weaning protocol and stewardship to reduce inappropriate use of iNO. The objective of this study was to evaluate our institutional iNO usage before and after implementation. METHODS: Single-center study comparing a retrospective control group to a prospective cohort after implementation of an iNO weaning protocol. All infants in the neonatal intensive care unit (NICU) who received iNO during the study timeframe were included. The primary outcome was duration of iNO per course. RESULTS: A total of 47 courses of iNO occurred during the pre-protocol timeframe compared with 37 courses in the post-protocol timeframe. Median iNO usage per course was 149 hours (IQR, 63-243) in the pre-protocol group versus 59 hours (IQR, 37-122) in the post-protocol group (p = 0.008). Length of stay was significantly longer in the pre-protocol group (p = 0.02), likely related to significantly longer ventilator days in the pre-protocol group (p = 0.02). Compliance with initiation of weaning when recommended per the protocol was 72%, and the incidence of successful weaning was 74%. CONCLUSIONS: The implementation of an iNO weaning protocol in the NICU significantly decreased iNO usage by approximately 60% with no notable negative effects. Copyright. Pediatric Pharmacy Association. All rights reserved. For permissions, email: mhelms@pediatricpharmacy.org 2022.
OBJECTIVE: Inhaled nitric oxide (iNO) is an effective but expensive treatment of pulmonary hypertension in newborns, with limited data regarding weaning. Our institution implemented a multidisciplinary iNO weaning protocol and stewardship to reduce inappropriate use of iNO. The objective of this study was to evaluate our institutional iNO usage before and after implementation. METHODS: Single-center study comparing a retrospective control group to a prospective cohort after implementation of an iNO weaning protocol. All infants in the neonatal intensive care unit (NICU) who received iNO during the study timeframe were included. The primary outcome was duration of iNO per course. RESULTS: A total of 47 courses of iNO occurred during the pre-protocol timeframe compared with 37 courses in the post-protocol timeframe. Median iNO usage per course was 149 hours (IQR, 63-243) in the pre-protocol group versus 59 hours (IQR, 37-122) in the post-protocol group (p = 0.008). Length of stay was significantly longer in the pre-protocol group (p = 0.02), likely related to significantly longer ventilator days in the pre-protocol group (p = 0.02). Compliance with initiation of weaning when recommended per the protocol was 72%, and the incidence of successful weaning was 74%. CONCLUSIONS: The implementation of an iNO weaning protocol in the NICU significantly decreased iNO usage by approximately 60% with no notable negative effects. Copyright. Pediatric Pharmacy Association. All rights reserved. For permissions, email: mhelms@pediatricpharmacy.org 2022.
Authors: Mohamed Abdelgadir Adam; Paolo Goffredo; Linda Youngwirth; Randall P Scheri; Sanziana A Roman; Julie A Sosa Journal: Surgery Date: 2015-10-02 Impact factor: 3.982
Authors: D Davidson; E S Barefield; J Kattwinkel; G Dudell; M Damask; R Straube; J Rhines; C T Chang Journal: Pediatrics Date: 1999-08 Impact factor: 7.124
Authors: F Sessions Cole; Claudia Alleyne; John D E Barks; Robert J Boyle; John L Carroll; Deborah Dokken; William H Edwards; Michael Georgieff; Katherine Gregory; Michael V Johnston; Michael Kramer; Christine Mitchell; Josef Neu; DeWayne M Pursley; Walter M Robinson; David H Rowitch Journal: Pediatrics Date: 2011-01-10 Impact factor: 7.124
Authors: V Villamil; M J Aranda García; J M Sánchez Morote; R Ruiz Pruneda; M Fernández Ibieta; A Sánchez Sánchez; I Martínez Castaño; J Rojas-Ticona; M C Giménez Aleixandre; J I Ruiz Jiménez Journal: Cir Pediatr Date: 2017-01-25
Authors: David A Cook; Laurie J Pencille; Denise M Dupras; Jane A Linderbaum; V Shane Pankratz; John M Wilkinson Journal: PLoS One Date: 2018-01-31 Impact factor: 3.240